

# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## CD3 Monoclonal Antibody (17A2), Functional Grade, eBioscience

RRID:AB\_2865578

Type: Antibody

---

### Proper Citation

(Thermo Fisher Scientific Cat# 16-0032-38, RRID:AB\_2865578)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2865578](http://antibodyregistry.org/AB_2865578)

**Proper Citation:** (Thermo Fisher Scientific Cat# 16-0032-38, RRID:AB\_2865578)

**Target Antigen:** CD3

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: Flow, Functional

**Antibody Name:** CD3 Monoclonal Antibody (17A2), Functional Grade, eBioscience

**Description:** This monoclonal targets CD3

**Target Organism:** mouse

**Clone ID:** clone 17A2

**Antibody ID:** AB\_2865578

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** 16-0032-38

**Record Creation Time:** 20251216T073842+0000

**Record Last Update:** 20260225T231413+0000

---

### Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (17A2), Functional Grade, eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (17A2), Functional Grade, eBioscience.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Lv Q, et al. (2024) CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacological research, 202, 107126.

Deng G, et al. (2022) Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. Journal for immunotherapy of cancer, 10(10).

Wang B, et al. (2021) CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell. Journal for immunotherapy of cancer, 9(8).